Navigation Links
Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients
Date:6/11/2009

SEATTLE, June 11 /PRNewswire/ -- Neurim Pharmaceuticals (http://www.neurim.com) presented today the preliminary results of a large-scale Phase III study of Circadin(R) 2mg, prolonged release melatonin in insomnia, demonstrating long term efficacy and safety in elderly patients. The results were reported in the Late Breaking Abstracts session of SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, (APSS) held at Seattle, Washington. The SLEEP meeting attracts the largest audience of sleep specialists in world.

Circadin(R) http://www.Circadin.info) is a novel sleep medicine that has been approved by the European Commission pharmaceutical regulatory agency and the Israeli Ministry of Health for the short-term treatment of primary insomnia, characterized by poor quality of sleep in patients who are aged 55 and over. The approval is based on clinical studies showing positive effects on sleep quality, sleep induction, and most importantly next day alertness and functioning.

The new double blind placebo controlled trial with more than 790 insomnia patients aged 18-80, shows that 6 months continuous treatment with Circadin(R) is both safe and efficacious. The trial demonstrated improvements in sleep latency, quality of sleep and morning alertness particularly in elderly patients, with no withdrawal symptoms and rebound insomnia. "We are very excited about these preliminary Phase III results" said Professor Nava Zisapel, CSO of Neurim Pharmaceuticals, "because Circadin(R), previously shown to be a unique short term treatment for poor sleep quality, has now demonstrated long term efficacy and safety."

About Circadin(R)

Circadin(R) http://www.Circadin.info) is the first and only IP-protected prolonged-release melatonin to be approved as an ethical drug by health authorities. Administration of Circadin(R) to patients with primary insomnia improves sleep quality and morning alertness and facilitates sleep onset in patients aged 55 or over. Currently commercialized in Europe by H.Lundbeck A/S and Nycomed, and in Israel by Teva, Circadin(R) is undergoing registration in US, Asia-Pacific and Latin American markets.

About Neurim Pharmaceuticals

Neurim Pharmaceuticals (http://www.neurim.com) is headquartered in Israel with offices in Switzerland and the UK. The company was founded in 1991 and is focused on drug discovery and development of treatments for age-related disorders, primarily in the central nervous system (CNS).

    For More information:

    Eran Schenker, MD
    Medical Director & Corporate Business Development
    Neurim Pharmaceuticals Ltd.
    Tel: +972-3-7684914 Cell: +972-52-6689944
    EranS@Neurim.com



'/>"/>
SOURCE Neurim Pharmaceuticals LTD
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Jubilant to Work With Endo Pharmaceuticals on Drug Development
2. Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)
3. ADVENTRX Pharmaceuticals Announces Financing
4. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
5. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
6. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
7. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
8. Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
9. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
10. VIA Pharmaceuticals DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
11. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... PARK, Calif. , Feb. 4, 2016   DelMar ... biopharmaceutical company focused on the development and commercialization of new ... 18 th Annual BIO CEO & Investor Conference ... in New York, NY . ... an update on the ongoing clinical trial of VAL-083 ...
(Date:2/4/2016)... 4, 2016 Sinovac Biotech Ltd. ("Sinovac" or ... of biopharmaceutical products in China , ... of directors received on February 4, 2016 a preliminary ... consortium comprised of PKU V-Ming ( Shanghai ... CICC Qianhai Development ( Shenzhen ) Fund ...
(Date:2/3/2016)... DIEGO , Feb. 3, 2016   ... company with the first pluripotent stem cell-derived islet ... diabetes in clinical-stage development, today announced that ViaCyte ... Pharmaceutical Companies of Johnson & Johnson, have agreed ... group into ViaCyte.  The agreement provides ViaCyte with ...
(Date:2/3/2016)... NEW YORK and HOLLISTON, Mass., Feb. 3, ... (Nasdaq: HART ), a biotechnology company developing ... esophagus, trachea and bronchus, today announced that CEO ... BIO CEO & Investor Conference on ... in New York City . ...
Breaking Biology Technology:
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
(Date:1/20/2016)... Jan. 20, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce the ... achievements are the result of the company,s laser focus ... eClinical , it,s comprehensive, easy-to-use and highly affordable ... --> Key MedNet growth achievements in 2015 include: ...
(Date:1/13/2016)... --> --> ... report titled - Biometric Sensors Market - Global Industry Analysis, ... to the report, the global biometric sensors market was valued at ... US$1,625.8 mn by 2023, expanding at a CAGR of ... the biometric sensors market is expected to reach 1,799.6 ...
Breaking Biology News(10 mins):